Whole Foods merger complaint
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission issues an amended complaint Sept. 8 against Whole Foods' acquisition of Wild Oats Markets, claiming the already-completed merger is "substantially reducing or eliminating competition in the operation of premium natural and organic supermarkets" in several geographic markets. The respondent has until Sept. 26 to file a response. FTC's complaint follows a same-day scheduling conference in which an administrative law judge from the agency laid out a timeline for filings and discovery leading up to a hearing before the commission on Feb. 16, 2009. The amended complaint filing was enabled by a July decision by the U.S. Court of Appeals for the District of Columbia Circuit, which reversed a lower court's ruling against FTC's motion for a preliminary injunction against the merger (1"The Tan Sheet" Aug. 18, 2008, p. 6). Whole Foods filed a petition Aug. 26 for a rehearing before the appeals court
You may also be interested in...
Whole Foods Merger Ruling Could “Embolden” Antitrust Activity – Attorney
An appeals court's questions about a merger in a key market for dietary supplement manufacturers - the Whole Foods/Wild Oats Markets deal - may impede similar deals across all U.S. industries, an antitrust law expert says
Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
ESMO: Daiichi's HER3-Targeting ADC Shows Promise, Particularly In Resistant Tumors
HER3 may be a new target for anticancer antibody-drug conjugates; clinical investigators posted promising early stage clinical results with Daiichi Sankyo’s HER3 targeting antibody-drug conjugate, patritumab deruxtecan, at the recent ESMO virtual meeting.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: